328 related articles for article (PubMed ID: 37426654)
1. Molecular mechanisms of immunotherapy resistance in triple-negative breast cancer.
Zheng Y; Li S; Tang H; Meng X; Zheng Q
Front Immunol; 2023; 14():1153990. PubMed ID: 37426654
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
3. Single peptides and combination modalities for triple negative breast cancer.
Razazan A; Behravan J
J Cell Physiol; 2020 May; 235(5):4089-4108. PubMed ID: 31642059
[TBL] [Abstract][Full Text] [Related]
4. Triple negative breast cancer (TNBC): Non-genetic tumor heterogeneity and immune microenvironment: Emerging treatment options.
So JY; Ohm J; Lipkowitz S; Yang L
Pharmacol Ther; 2022 Sep; 237():108253. PubMed ID: 35872332
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Immune Resistance Mechanisms in TNBC: Dual Effects Inside and Outside the Tumor.
Xu J; Gan C; Yu S; Yao S; Li W; Cheng H
Clin Breast Cancer; 2024 Feb; 24(2):e91-e102. PubMed ID: 38016911
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modulations in triple-negative breast cancer: Therapeutic implications for tumor microenvironment.
Zhou L; Yu CW
Pharmacol Res; 2024 Jun; 204():107205. PubMed ID: 38719195
[TBL] [Abstract][Full Text] [Related]
7. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
Isaacs J; Anders C; McArthur H; Force J
Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of immunotherapy in triple-negative breast cancer.
Howard FM; Pearson AT; Nanda R
Breast Cancer Res Treat; 2022 Aug; 195(1):1-15. PubMed ID: 35834065
[TBL] [Abstract][Full Text] [Related]
10. Innate immunity as a target for novel therapeutics in triple negative breast cancer.
Borgovan T; Yanamandra N; Schmidt H
Expert Opin Investig Drugs; 2022 Aug; 31(8):781-794. PubMed ID: 35791862
[TBL] [Abstract][Full Text] [Related]
11. Emerging drug targets for triple-negative breast cancer: a guided tour of the preclinical landscape.
Xie X; Lee J; Iwase T; Kai M; Ueno NT
Expert Opin Ther Targets; 2022 May; 26(5):405-425. PubMed ID: 35574694
[TBL] [Abstract][Full Text] [Related]
12. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
13. Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Bai X; Ni J; Beretov J; Graham P; Li Y
Cancer Lett; 2021 Jan; 497():100-111. PubMed ID: 33069769
[TBL] [Abstract][Full Text] [Related]
14. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
Hall PE; Schmid P
Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
[No Abstract] [Full Text] [Related]
15. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
16. STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review.
Qin JJ; Yan L; Zhang J; Zhang WD
J Exp Clin Cancer Res; 2019 May; 38(1):195. PubMed ID: 31088482
[TBL] [Abstract][Full Text] [Related]
17. Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer.
Agostinetto E; Losurdo A; Nader-Marta G; Santoro A; Punie K; Barroso R; Popovic L; Solinas C; Kok M; de Azambuja E; Lambertini M
Expert Opin Investig Drugs; 2022 Jun; 31(6):567-591. PubMed ID: 35240902
[TBL] [Abstract][Full Text] [Related]
18. Predictive biomarkers of response to immunotherapy in triple-negative breast cancer - state of the art and future perspectives.
Tancoš V; Blichárová A
Klin Onkol; 2023; 36(1):28-34. PubMed ID: 36868830
[TBL] [Abstract][Full Text] [Related]
19. Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer.
Dixon-Douglas J; Loibl S; Denkert C; Telli M; Loi S
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35649211
[TBL] [Abstract][Full Text] [Related]
20. Contribution of the tumor and obese microenvironment to triple negative breast cancer.
Kaul K; Misri S; Ramaswamy B; Ganju RK
Cancer Lett; 2021 Jul; 509():115-120. PubMed ID: 33798632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]